ライフサイエンスコーパス: radiosurgery

1 deficits appeared more than 28 months after radiosurgery.

2 patients (2 percent) within four years after radiosurgery.

3 application will be image guidance in proton radiosurgery.

4 ical patients, 6-12 wk after radiotherapy or radiosurgery.

5 treated by conventional radiotherapy and/or radiosurgery.

6 nventional radiation as well as stereotactic radiosurgery.

7 e surgical bed was treated with stereotactic radiosurgery.

8 , whole-brain radiotherapy, and stereotactic radiosurgery.

9 cant associations in studies of stereotactic radiosurgery.

10 dverse events were noted during or after the radiosurgery.

11 T), with or without surgery, or stereotactic radiosurgery.

12 ation, radiofrequency ablation, and recently radiosurgery.

13 5-mm value for conventional radiotherapy and radiosurgery.

14 e measured before treatment with gamma knife radiosurgery.

15 herapy, surgical resection, and stereotactic radiosurgery.

16 induced to undergo apoptosis by gamma knife radiosurgery.

17 nitial sites (surgery: 59% to 27%, P < .001; radiosurgery: 31% to 19%, P = .040) and at new sites (su

18 at new sites (surgery: 42% to 23%, P = .008; radiosurgery: 48% to 33%, P = .023).

19 73 metastases at 20 weeks after stereotactic radiosurgery; 61% maintained local control at 2 years.

20 ularly image-guided surgery and stereotactic radiosurgery, allows clinicians who are focused on the t

21 ion, neurosurgical excision, or stereotactic radiosurgery alone or in combination).

22 ons--167 were assigned WBRT and stereotactic radiosurgery and 164 were allocated WBRT alone.

23 can include surgical excision, stereotactic radiosurgery and embolization.

24 interstitial brachy-therapy or stereotactic radiosurgery and is associated with a significantly lowe

25 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to adjuvant WBRT (30

26 Of 359 patients, 199 underwent radiosurgery, and 160 underwent surgery.

27 normal in 76 percent of the patients before radiosurgery, and 20 percent had useful hearing.

28 ts (47 percent) were employed at the time of radiosurgery, and 37 (69 percent) remained so.

29 apy (WBRT), surgical resection, stereotactic radiosurgery, and chemotherapy.

30 d on indications for resection, stereotactic radiosurgery, and fractionated radiotherapy for patients

31 w brain lesion was treated with stereotactic radiosurgery, and he began systemic therapy with ipilimu

32 nal treatment planning systems, stereotactic radiosurgery, and intensity modulated radiation therapy

33 scular embolisation techniques, stereotactic radiosurgery, and microsurgery, allowing effective multi

34 nsity-modulated radiotherapy, brachytherapy, radiosurgery, and photodynamic therapy for recurrent hig

35 on therapy, surgical resection, stereotactic radiosurgery, and systemic therapy.

36 lan-Meier plots of survival from the date of radiosurgery, and univariate and multivariate analyses.

37 ch as whole-brain radiotherapy, stereotactic radiosurgery, and/or surgical resection.

38 s) by neurosurgical excision or stereotactic radiosurgery are imprecise and vary between studies.

39 Surgery and radiosurgery are only local therapies and the patients f

40 The goals of radiosurgery are the long-term prevention of tumor growt

41 fects, especially important for stereotactic radiosurgery, are unknown.

42 rapy (WBRT) or WBRT followed by stereotactic radiosurgery boost.

43 As an alternative, radiosurgery can be done for small tumours, or fractiona

44 sinus lesions and sellar lesions (for which radiosurgery can be offered as adjuvant or in certain ca

45 Radiosurgery can provide long-term control of acoustic n

46 calization and multiplicity make surgery and radiosurgery challenging and morbidity is often consider

47 The paradigm shift resulting from radiosurgery continues to alter the landscape of related

48 uated 162 consecutive patients who underwent radiosurgery for acoustic neuromas between 1987 and 1992

49 The use stereotactic radiosurgery for brain metastases has expanded recently

50 derwent linear accelerator-based stereotaxic radiosurgery for brain metastases identified by computed

51 view the recent publications of stereotactic radiosurgery for brain tumors.

52 s predicting the outcomes after stereotactic radiosurgery for cerebral arteriovenous malformations (A

53 first multi-institutional phase III trial of radiosurgery for patients with brain metastases to numer

54 nally, as radiation therapy and stereotactic radiosurgery for pituitary tumors gains more widespread

55 Currently, radiosurgery for these lesions produces similar results.

56 Survival after radiosurgery for three or more metastases was similar to

57 ogic complication resulting from gamma knife radiosurgery (GKRS) has not yet been reported.

58 icacy and safety of multisession gamma knife radiosurgery (GKRS) in benign, well-circumscribed tumors

59 vival advantage in the WBRT and stereotactic radiosurgery group for patients with a single brain meta

60 In the radiosurgery group, 100 patients were allocated to OBS,

61 Radiosurgery has achieved satisfactory obliteration of d

62 lanning made in the past decade, gamma knife radiosurgery has become more and more an established tre

63 Radiosurgery has been recently utilized in the treatment

64 Recently, stereotactic radiosurgery has emerged as an increasingly important al

65 te its controversial beginning, stereotactic radiosurgery has rapidly gained acceptance among neurosu

66 Literature on extensive intracranial radiosurgery has unequivocally demonstrated the favorabl

67 Recent publications of stereotactic radiosurgery have increased our understanding of the use

68 Existing therapeutic options, surgery and radiosurgery, including new data on the latter will be r

69 Radiosurgery is a promising new technology, but is still

70 Radiosurgery is an effective adjuvant therapy against me

71 ted radiotherapy or stereotactic single-dose radiosurgery is increasing for meningiomas that are inco

72 Gamma ventral capsulotomy (GVC) radiosurgery is intended to minimize side effects while

73 sidered radiotherapy resistant, stereotactic radiosurgery is recommended; if the BMs are greater than

74 Stereotactic radiosurgery is the principal alternative to microsurgic

75 tomy as treatment for localized disease, and radiosurgery may be as effective as surgical resection i

76 Stereotactic radiosurgery may offer a survival advantage (in a select

77 d 5.4 (95% CI 4.5 to 6.4) after stereotactic radiosurgery (median follow-up 4.1 years).

78 dy shows that adjuvant WBRT after surgery or radiosurgery of a limited number of brain metastases fro

79 RT) with observation after either surgery or radiosurgery of a limited number of brain metastases in

80 of functional independence after surgery or radiosurgery of brain metastases.

81 er to reduce dose to normal brain tissue for radiosurgery of multiple metastases with single-isocente

82 ived 13.5-18-Gy single-fraction stereotactic radiosurgery; one received 19.8 Gy in three fractions, o

83 Treatment concepts combining surgery and radiosurgery or fractionated radiotherapy, which enable

84 After radiosurgery or surgery of a limited number of brain met

85 nt data were available to assess gamma-knife radiosurgery or vagal nerve stimulation.

86 a large tumor, single-fraction stereotactic radiosurgery, or use of more than 6 Gy per fraction.

87 provide the best possible predictions of AVM radiosurgery outcomes of any method to date, identify a

88 We aimed to assess whether stereotactic radiosurgery provided any therapeutic benefit in a rando

89 Gamma knife radiosurgery remains a compelling treatment for lesions

90 The safety, efficacy, and morbidity of radiosurgery (RS) must be established before it can be o

91 Retrospective radiosurgery (RS) reports found no survival difference w

92 he capabilities of image-guided stereotactic radiosurgery, separation surgery, vertebroplasty, and mi

93 After resection of a brain metastasis, SRS radiosurgery should be considered one of the standards o

94 WBRT and stereotactic radiosurgery should, therefore, be standard treatment fo

95 ain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) delivered only to the radiographicall

96 ain radiation therapy (WBRT) to stereotactic radiosurgery (SRS) for the control of brain-tumours outw

97 explore the use of Gamma Knife stereotactic radiosurgery (SRS) for this common problem.

98 ective series, neurosurgery and stereotactic radiosurgery (SRS) may prolong survival in patients with

99 did this study to determine if stereotactic radiosurgery (SRS) to the surgical cavity improved time

100 However, stereotactic radiosurgery (SRS) to the surgical cavity is widely used

101 The concept of stereotactic radiosurgery (SRS) was first described by Lars Leksell i

102 nd includes surgical resection, stereotactic radiosurgery (SRS), and whole-brain radiation therapy (W

103 Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and

104 umor control in the brain after stereotactic radiosurgery (SRS), yet because of its association with

105 ived radiotherapy to the brain (stereotactic radiosurgery [SRS] or whole-brain radiotherapy [WBRT]),

106 nts with 1 to 3 brain metastases amenable to radiosurgery, SRS alone may be a preferred strategy.

107 been the integration of spinal stereotactic radiosurgery (SSRS), allowing delivery of tumoricidal ra

108 longed course of WBRT, surgery, stereotactic radiosurgery, systemic therapy, or a combination.

109 ed optic neuropathy are infrequent following radiosurgery to these areas, and perhaps radiation-induc

110 ence treatment in patients with stereotactic radiosurgery-treated metastases.

111 derived from the techniques of stereotactic radiosurgery used to treat lesions in the brain and spin

112 ts randomized to sham GVC received simulated radiosurgery using the same equipment.

113 re necessary to better define the utility of radiosurgery versus surgery in the management of patient

114 The median survival time after stereotactic radiosurgery was 53 weeks and correlated with systemic d

115 Radiosurgery was believed to have been successful by all

116 Rates of response to stereotactic radiosurgery were calculated.

117 s, even when tumor apoptosis was induced via radiosurgery, which leads to efficient "loading" of the

118 The only potential treatment is surgery/radiosurgery, which often results in loss of function of

119 ent are typically utilized: pharmacological, radiosurgery with gamma radiation, and external beam rad